The Myeloproliferative Neoplasms Research Consortium (MPN-RC), funded by the National Cancer Institute (NCI), has launched a new website showcasing our innovative laboratory and clinical research to cure MPNs. You can find information on our collaborative efforts to translate findings from our laboratory based studies into novel clinical trials to evaluate treatments for patients living with MPNs. Visit MPN-RC to read more about our exciting research and our leaders who are spearheading this important research and subscribe for updates.
Read more about MPN-RC
Researchers are seeking patients with Myeloproliferative Neoplasm (MPN) to answer questions about personal habits and thoughts in an online survey. The purpose of our survey is to learn more about how lifestyle affects patients with MPN. We want to hear from ALL MPN patients. With this in mind, we hope you will respond to the questionnaire below. The survey should take around 15 minutes to complete.
Read more about MPN Pain Management and Patient Habit Survey
Since 2013, the MPN Heroes Recognition Program has recognized the people and organizations that have dedicated themselves to improving the lives of people with MPNs. The program focuses on the three “classical” MPNs—or what are known as Philadelphia chromosome–negative MPNs.
2022 marks the tenth anniversary of the MPN Heroes Recognition Program, sponsored by Incyte Corporation and CURE magazine. Our goal is to create as many opportunities as possible for people with MPNs to be heard and to be supported, so more solutions and treatment options will emerge.
Created in the spirit of fostering community, the program recognizes patients, Healthcare Professionals, caregivers, advocates, and organizations that contribute to bringing understanding, compassion, and strength to the MPN community. Nominate your hero today!
Read more about Nominate your Hero today
Ruben Mesa, M.D., Chair of Hematology and Oncology at Mayo Clinic in Arizona, discusses common patient questions regarding myeloproliferative neoplasms with John Camoriano, M.D., medical oncology consultant at Mayo Clinic.
Read more about Answering Common Patient Questions on Myeloproliferative Neoplasms – Mayo Clinic
Ruben Mesa, M.D., hematologist and Deputy Director of the Mayo Clinic Cancer Center in Arizona, provides his top ten recommendations for battling the fatigue associated with a diagnosis of myeloproliferative neoplasm.
Read more about Top 10 Tips for Battling the Fatigue Associated with Myeloproliferative Neoplasms – Mayo Clinic
Diagnosis of MDS or MDS/MPN must begin with morphology (analysis of the form and structure of patient blood or bone marrow cells). When used alone, today’s advanced techniques to study genes and chromosomes don’t give enough information to find out what type of MDS or MDS/MPN a patient has.
Read more about Drivers or Passengers? Genetics of MDS and MDS/MPN
Conventional cytogenetics is a method to analyze chromosomes. Researchers and clinicians use conventional cytogenetics to diagnose blood disorders, predict outcomes in patients with these disorders, and develop new treatments that target genetic changes associated with a disease.
Read more about There is Always Room for Improvement: Changing Role of Chromosome Analysis in MDS and MDS/MPN.